SBFM-PL4
Oncology / Multi-Drug Resistance
PreclinicalIND-Enabling
Key Facts
Indication
Oncology / Multi-Drug Resistance
Phase
Preclinical
Status
IND-Enabling
Company
About Sunshine Biopharma
Sunshine Biopharma's mission is to develop novel therapeutics for cancer and life-threatening diseases. Its key achievement is establishing a hybrid business model, combining revenue-generating generic drug sales in Canada with proprietary R&D focused on overcoming chemotherapy resistance and developing mRNA vaccines. The company's strategy is to use the cash flow from its commercial subsidiary to fund the advancement of its oncology pipeline, mitigating the financial volatility typical of early-stage biotechs. Its lead program, SBFM-PL4, represents a novel approach to a long-standing challenge in oncology.
View full company profile